Congress targets preventable infant deaths from syphilis with Medicaid guidance
S. 2004 — Maternal and Infant Syphilis Prevention Act · Filed by Martin Heinrich (D-NM) · 1 cosponsor · Introduced Jun 10, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the Secretary of Health and Human Services to issue guidance within 12 months on best practices for screening and treating congenital syphilis (syphilis transmitted from mother to infant) under Medicaid and the Children's Health Insurance Program (CHIP). The guidance covers expanded screening for pregnant women and newborns, provider and patient education, telehealth integration, third-trimester and delivery-time testing, and treatment improvements. The Secretary must report to Congress within 2 years on implementation.
Why we flagged it
The bill is a straightforward public health measure directing HHS to issue evidence-based guidance on preventing a documented infectious disease crisis affecting pregnant women and infants. It contains no tax provisions, subsidies, or regulatory carve-outs—only a mandate for guidance and a reporting requirement.
What the text implies
- Guidance may enable states to use Medicaid section 1115 waivers to expand screening beyond current coverage limits, potentially shifting costs or eligibility rules—implementation details will depend on state-level policy choices not specified in the bill.
- Telehealth integration and multilingual resources may require state infrastructure investment; bill does not appropriate funds, so implementation depends on existing Medicaid/CHIP budgets or state appropriations.
The full analysis lists 3 implications of this text.
Who stands to gain
diagnostic testing providers (labs, point-of-care test manufacturers); telehealth platforms and providers; maternal-fetal medicine specialists and pediatricians